The American Medical Association (AMA) House of Delegates (HOD) convened its Annual Meeting in Chicago this past June, bringing together a vast assembly of physicians, residents, and medical students to deliberate on the most pressing issues facing the modern healthcare landscape. Among the primary participants in this legislative process were representatives from the Endocrine Society, including Naykky Singh Ospina, MD, Amanda Bell, MD, and Daniel Spratt, MD. This delegation served as the primary voice for endocrinology, advocating for policy shifts that recognize the complex hormonal and metabolic underpinnings of chronic diseases. The meeting served as a critical juncture for the medical community to formalize its stance on emerging therapies, insurance parity, and the persistent gaps in women’s healthcare.
The AMA House of Delegates serves as the legislative and policy-making body of the AMA, meeting twice a year to consider changes to the organization’s massive compendium of policies. These policies often serve as the foundation for federal and state lobbying efforts, influencing how the AMA interacts with the Centers for Medicare & Medicaid Services (CMS), private insurers, and the United States Congress. For the Endocrine Society, the June meeting was an opportunity to push for systemic changes that would allow specialized providers to better manage the burgeoning obesity epidemic and address disparities in maternal and reproductive health.
Advancing Parity in Obesity Care and Treatment Access
A central focus of the Endocrine Society’s advocacy during the June meeting was the pursuit of insurance parity for obesity care. For decades, obesity was often viewed through a lens of personal responsibility rather than as a chronic, relapsing disease. However, the medical consensus has shifted significantly, particularly following the AMA’s own 2013 resolution that officially classified obesity as a disease. Despite this classification, insurance coverage for comprehensive obesity management has remained inconsistent and, in many cases, non-existent.
The Endocrine Society delegation co-sponsored a landmark resolution aimed at addressing this disparity. The resolution advocated for insurance parity across three main pillars of obesity treatment: metabolic and bariatric surgery, pharmacotherapy, and behavioral therapy. The delegates argued that treating obesity should be held to the same standard as treating other chronic conditions, such as hypertension or type 2 diabetes. By securing AMA support for this resolution, the Society aims to dismantle the "coverage gap" that prevents millions of Americans from accessing evidence-based care.
The necessity of this policy shift is underscored by current epidemiological data. According to the Centers for Disease Control and Prevention (CDC), the prevalence of obesity in the United States reached approximately 41.9% between 2017 and 2020. This rise in prevalence is accompanied by a staggering economic burden; the annual medical cost of obesity in the U.S. was nearly $173 billion in 2019 dollars. Medical costs for adults who had obesity were $1,864 higher than those with a healthy weight. By advocating for insurance parity, the Endocrine Society and the AMA are pushing for a preventative approach that could potentially lower long-term healthcare expenditures by mitigating the complications associated with obesity, such as cardiovascular disease, certain cancers, and kidney failure.
The Role of Pharmacotherapy and New Treatment Paradigms
The advocacy for parity is particularly timely given the rapid advancements in obesity pharmacotherapy. The emergence of glucagon-like peptide-1 (GLP-1) receptor agonists has revolutionized the field, offering weight loss results that previously were only achievable through surgical intervention. However, the high cost of these medications—often exceeding $1,000 per month without insurance—has created a tiered system of health where only the wealthy or those with premium insurance plans can access the most effective treatments.
During the HOD deliberations, the Endocrine Society delegates emphasized that endocrinologists are uniquely positioned to manage these complex treatments. They argued that without insurance parity, the medical community cannot fulfill its ethical obligation to provide the standard of care to all patients, regardless of socioeconomic status. The resolution passed by the HOD calls for the AMA to support legislation and regulation that requires public and private payers to provide coverage for the full spectrum of evidence-based obesity treatments. This includes challenging the 1993 federal law that currently prohibits Medicare from covering weight-loss drugs, a major hurdle for older Americans seeking metabolic health improvements.
Prioritizing Women’s Health and Reproductive Equity
In addition to obesity care, the Endocrine Society delegation played a pivotal role in supporting resolutions focused on women’s health. Endocrinology is deeply intertwined with women’s health, encompassing everything from polycystic ovary syndrome (PCOS) and thyroid disorders to menopause and reproductive endocrinology. The June meeting saw the AMA House of Delegates reaffirm its commitment to protecting the patient-physician relationship and ensuring that clinical decisions remain in the hands of medical professionals and their patients.
The Society supported measures aimed at improving maternal health outcomes and addressing the rising rates of maternal mortality in the United States, which disproportionately affect women of color. Data from the National Center for Health Statistics indicates that the maternal mortality rate for non-Hispanic Black women in 2021 was 69.9 deaths per 100,000 live births, which is 2.6 times the rate for non-Hispanic White women. The delegates advocated for policies that expand postpartum care and ensure that endocrine-related complications during pregnancy, such as gestational diabetes and preeclampsia, are managed through integrated, multidisciplinary care teams.
Furthermore, the delegation participated in discussions regarding the impact of legislative interference in medical practice. The Endocrine Society has been a vocal advocate for the preservation of access to evidence-based reproductive healthcare, noting that hormonal health is essential to overall well-being. By aligning with the AMA HOD on these issues, the Society helps to solidify a unified front against policies that would restrict a physician’s ability to provide comprehensive care.
A Chronology of Advocacy: From the Clinic to the House of Delegates
The path to the June meeting in Chicago is the result of months of preparation and years of evolving medical science. The chronology of these advocacy efforts reflects a broader shift in how the medical establishment views metabolic health:
- 2013: The AMA officially recognizes obesity as a disease, setting the stage for future policy changes regarding treatment and reimbursement.
- 2021-2022: The FDA approves new generations of highly effective obesity medications, sparking a national conversation about access and affordability.
- Early 2024: The Endocrine Society’s Advocacy and Public Outreach Core Committee identifies obesity parity and women’s health as top legislative priorities for the upcoming AMA sessions.
- June 2024: Delegates Singh Ospina, Bell, and Spratt represent the Society in Chicago, testifying before reference committees and building coalitions with other specialty societies like the American College of Surgeons and the American College of Physicians.
- Post-June 2024: The AMA begins the process of translating HOD resolutions into active lobbying strategies for the 2025 legislative session.
This timeline illustrates that the work performed in Chicago is not an isolated event but a critical link in a chain of advocacy aimed at modernizing the American healthcare system.
The Legislative Structure of the AMA House of Delegates
To understand the significance of the Endocrine Society’s participation, one must understand the mechanics of the AMA HOD. The House is often referred to as the "Parliament of Medicine." It is composed of delegates from every state medical association and over 170 national medical specialty societies. The democratic process involves the submission of "resolutions," which are then assigned to Reference Committees.
During the June meeting, delegates like Dr. Singh Ospina and her colleagues testified during these committee hearings. These hearings allow members to speak in support of or opposition to a resolution. Following the hearings, the Reference Committees produce reports with recommendations to the full House: to adopt, not adopt, or refer the resolution for further study. The Endocrine Society’s success in having its co-sponsored resolution on obesity parity adopted signifies a broad consensus within the medical community that the status quo is no longer acceptable.
Official Responses and Industry Implications
While the AMA’s internal deliberations are focused on policy, the external reactions from the healthcare industry and patient advocacy groups have been significant. Groups such as the Obesity Action Coalition (OAC) have lauded the AMA’s strengthened stance on treatment parity. "The recognition by the AMA and specialty societies like the Endocrine Society that obesity treatment must be covered as a standard medical benefit is a major victory for patients," a spokesperson for a national health advocacy group noted in a post-meeting summary.
From an industry perspective, the move toward parity could signal a shift in how pharmaceutical companies and insurers negotiate. If the AMA’s advocacy leads to the passage of the "Treat and Reduce Obesity Act" (TROA) in Congress, it would force a re-evaluation of drug pricing and insurance premiums. Analysts suggest that while initial costs for coverage might rise, the long-term reduction in "downstream" chronic disease costs would provide a net benefit to the healthcare system.
The Endocrine Society’s leadership expressed gratitude for the work of its delegates. In an internal communication following the meeting, the Society noted that the presence of Dr. Singh Ospina, Dr. Bell, and Dr. Spratt ensured that the specific nuances of endocrine science were integrated into the broader medical policy. This scientific grounding is essential for ensuring that AMA policies are not just well-intentioned, but clinically sound.
Broader Impact and Future Outlook
The implications of the June AMA meeting extend far beyond the conference rooms of Chicago. The policies adopted there will influence the AMA’s "Recovery Plan for America’s Physicians," which focuses on reducing administrative burden, supporting physician well-being, and advancing value-based care. For endocrinologists, the focus on obesity parity is a direct hit at the administrative burdens of "prior authorization," which frequently delays or denies necessary treatment for patients with metabolic disorders.
Looking forward, the Endocrine Society and the AMA will turn their attention to the Interim Meeting, usually held in November, where they will monitor the progress of these resolutions. The goal remains clear: to ensure that the healthcare system evolves at the same pace as medical innovation. As the delegation from the Endocrine Society demonstrated in Chicago, the voice of the specialist is vital in translating complex science into actionable policy that improves patient lives.
By championing parity in obesity care and advocating for the specific needs of women’s health, the Endocrine Society has helped set a new standard for medical advocacy. The resolutions passed in June provide a roadmap for a more equitable healthcare system where treatment is determined by clinical need and scientific evidence, rather than by insurance codes or outdated perceptions of disease. The work of Dr. Singh Ospina, Dr. Bell, and Dr. Spratt serves as a reminder that the future of medicine is shaped not only in the laboratory and the clinic but also in the legislative halls where the rules of practice are written.
